UNSPSC 51241125: Tafluprost

This classification denotes a prostaglandin analogue with the molecular formula C25H34F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1O6WQ6T7G3, chemically known as isopropyl (5z)-7-{(1r,2r,3r,5s)-2-((1e)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate but generally known as tafluprost, which bears US NIH Compound Identifier 6433101. European Medicines Agency schedules Tafluprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30776.

UNSPSC 51241125 Tafluprost, a Commodity code, encompasses ophthalmic pharmaceutical products supplied through state and local cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits generic and branded pharmaceuticals including tafluprost under multi-source supply contracts that serve participating state and local government health facilities. State and local issuing bodies procure pharmaceuticals under this code primarily through cooperative purchasing vehicles rather than individual agency RFPs; MMCAP operates as the primary mechanism, coordinating supply across multiple participating states and enabling member agencies to access negotiated pricing on identified National Drug Code products. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), certify cGMP and Drug Supply Chain Security Act compliance, carry required insurance including $5,000,000 commercial general liability per occurrence, and accept a 3 percent administrative fee on all purchases plus performance penalties ranging from $200 to $1,500 per violation.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products, with proposals due March 26, 2026, represents the most recent activity under this code. The solicitation covers multiple states including Minnesota and Oregon, with awarded contracts effective July 1, 2026. Evaluation weighting emphasizes price competitiveness at 75 percent, with 10 percent for fixed pricing, 5 percent for administrative fee format compliance, 5 percent for EDI capability, and 5 percent for agreement to the 3 percent administrative fee. Vendors must demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, and all products require FDA compliance with minimum one-year expiration dates from manufacture and six-month shelf life at delivery. MMCAP reserves multi-award authority and will make awards based on therapeutic considerations, product availability, patient safety, and member-specific needs; specific award values are not disclosed in available materials.